{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:08:10Z","timestamp":1785852490173,"version":"3.56.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T00:00:00Z","timestamp":1765670400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016806","name":"Natural Science Foundation of Nantong Municipality","doi-asserted-by":"publisher","award":["JC2024071"],"award-info":[{"award-number":["JC2024071"]}],"id":[{"id":"10.13039\/100016806","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82300412"],"award-info":[{"award-number":["82300412"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.intimp.2025.116037","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T19:20:37Z","timestamp":1765912837000},"page":"116037","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Study on the mechanism of PSENEN in modulating cisplatin resistance in NSCLC through stromal cell interactions"],"prefix":"10.1016","volume":"169","author":[{"given":"Zhenyu","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyi","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianle","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2025.116037_bb0005","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.mcna.2018.12.006","article-title":"Lung Cancer","volume":"103","author":"Nasim","year":"2019","journal-title":"Med. Clin. North Am."},{"key":"10.1016\/j.intimp.2025.116037_bb0010","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","article-title":"The global burden of lung cancer: current status and future trends","volume":"20","author":"Leiter","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.116037_bb0015","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1007\/s11427-018-9461-5","article-title":"Analysis of status and countermeasures of cancer incidence and mortality in China","volume":"62","author":"Wu","year":"2019","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.intimp.2025.116037_bb0020","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.molmed.2019.04.012","article-title":"Abandoning the notion of non-small cell lung Cancer","volume":"25","author":"Relli","year":"2019","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.intimp.2025.116037_bb0025","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1200\/JCO.20.01605","article-title":"Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung Cancer","volume":"39","author":"Borghaei","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.116037_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115891","article-title":"Advances and challenges in the treatment of lung cancer","volume":"169","author":"Li","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2025.116037_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104080","article-title":"Neoadjuvant therapy in non-small cell lung cancer","volume":"190","author":"Grant","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.intimp.2025.116037_bb0045","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.intimp.2025.116037_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26082382","article-title":"Elucidating role of reactive oxygen species (ROS) in cisplatin chemotherapy: a focus on molecular pathways and possible therapeutic strategies","volume":"26","author":"Mirzaei","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.intimp.2025.116037_bb0055","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/onc.2011.384","article-title":"Molecular mechanisms of cisplatin resistance","volume":"31","author":"Galluzzi","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.intimp.2025.116037_bb0060","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41420-022-01217-9","article-title":"CUR5g, a novel autophagy inhibitor, exhibits potent synergistic anticancer effects with cisplatin against non-small-cell lung cancer","volume":"8","author":"Chen","year":"2022","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.intimp.2025.116037_bb0065","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41419-019-1597-y","article-title":"Targeting HDAC\/OAZ1 axis with a novel inhibitor effectively reverses cisplatin resistance in non-small cell lung cancer","volume":"10","author":"Sun","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2025.116037_bb0070","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1007\/s12672-025-02926-0","article-title":"Overcoming therapeutic resistance in driver-negative NSCLC: immunomodulatory mechanisms and clinical efficacy of Camrelizumab-chemotherapy combination in a real-world cohort","volume":"16","author":"Ge","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.intimp.2025.116037_bb0075","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3478","article-title":"circANKRD28 inhibits cisplatin resistance in non-small-cell lung cancer through the miR-221-3p\/SOCS3 axis","volume":"25","author":"Song","year":"2023","journal-title":"J. Gene Med."},{"key":"10.1016\/j.intimp.2025.116037_bb0080","article-title":"Discovery of a tribenzophenazine analog for binding to the KRAS mRNA G-quadruplex structures in the cisplatin-resistant non-small cell lung cancer","volume":"301","author":"Wang","year":"2025","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2025.116037_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.615967","article-title":"Identification of proteins deregulated by platinum-based chemotherapy as novel biomarkers and therapeutic targets in non-small cell lung Cancer","volume":"11","author":"Ryan","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2025.116037_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105533","article-title":"Functional and topological analysis of PSENEN, the fourth subunit of the gamma-secretase complex","volume":"300","author":"Serneels","year":"2024","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2025.116037_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.933855","article-title":"Immunological and prognostic analysis of PSENEN in low-grade gliomas: an immune infiltration-related prognostic biomarker","volume":"15","author":"Chen","year":"2022","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.intimp.2025.116037_bb0100","first-page":"4614","article-title":"Evaluation of the prognostic significances of gamma-secretase genes in pancreatic cancer","volume":"17","author":"Jeon","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.intimp.2025.116037_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079249","article-title":"Gamma-secretase components as predictors of breast cancer outcome","volume":"8","author":"Peltonen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2025.116037_bb0110","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/34910","article-title":"Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein","volume":"391","author":"De Strooper","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2025.116037_bb0115","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejphar.2006.06.078","article-title":"Pathogenic mechanisms in Alzheimer\u2019s disease","volume":"545","author":"Pastorino","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.intimp.2025.116037_bb0120","first-page":"271","article-title":"Cancer treatment and survivorship statistics, 2016","volume":"66","author":"Miller","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.intimp.2025.116037_bb0125","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.31557\/APJCP.2021.22.4.1279","article-title":"The Association of Aging-Related Polymorphisms with susceptibility to lung Cancer: a case-control study in a Japanese population","volume":"22","author":"Furuie","year":"2021","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.intimp.2025.116037_bb0130","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1038\/s41591-018-0096-5","article-title":"Phenotype molding of stromal cells in the lung tumor microenvironment","volume":"24","author":"Lambrechts","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2025.116037_bb0135","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12943-019-0959-5","article-title":"Hypoxic BMSC-derived exosomal miRNAs promote metastasis of lung cancer cells via STAT3-induced EMT","volume":"18","author":"Zhang","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2025.116037_bb0145","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/cac2.12359","article-title":"Non-small cell lung cancer in China","volume":"42","author":"Chen","year":"2022","journal-title":"Cancer Commun. (Lond.)"},{"key":"10.1016\/j.intimp.2025.116037_bb0150","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/978-3-319-40389-2_6","article-title":"Chemotherapy for advanced non-small cell lung Cancer","volume":"170","author":"Dietrich","year":"2016","journal-title":"Cancer Treat. Res."},{"key":"10.1016\/j.intimp.2025.116037_bb0155","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.gendis.2022.07.023","article-title":"Non-small cell lung carcinoma (NSCLC): implications on molecular pathology and advances in early diagnostics and therapeutics","volume":"10","author":"Padinharayil","year":"2023","journal-title":"Genes Dis"},{"key":"10.1016\/j.intimp.2025.116037_bb0160","doi-asserted-by":"crossref","first-page":"88","DOI":"10.14715\/cmb\/2017.63.6.18","article-title":"Lung cancer: analysis of biomarkers and methods of diagnostic and prognostic value","volume":"63","author":"Yadav","year":"2017","journal-title":"Cell. Mol. Biol. (Noisy-le-Grand)"},{"key":"10.1016\/j.intimp.2025.116037_bb0165","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1055\/s-0036-1592337","article-title":"Predictive and prognostic biomarkers in non-small cell lung Cancer","volume":"37","author":"Thakur","year":"2016","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"10.1016\/j.intimp.2025.116037_bb0170","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/bmj.311.7010.899","article-title":"Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small cell lung Cancer collaborative group","volume":"311","year":"1995","journal-title":"BMJ"},{"key":"10.1016\/j.intimp.2025.116037_bb0175","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1200\/JCO.18.01534","article-title":"Does platinum-based chemotherapy still have a role in first-line treatment of advanced non-small-cell lung Cancer?","volume":"37","author":"Lisberg","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.116037_bb0180","first-page":"172","article-title":"Cisplatin resistance: preclinical findings and clinical implications","volume":"1806","author":"Koberle","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.intimp.2025.116037_bb0185","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.intimp.2025.116037_bb0190","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nature10760","article-title":"The DNA damage response and cancer therapy","volume":"481","author":"Lord","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2025.116037_bb0195","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/sj.onc.1210220","article-title":"The Bcl-2 apoptotic switch in cancer development and therapy","volume":"26","author":"Adams","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.intimp.2025.116037_bb0200","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/nrc1503","article-title":"Targeting the mitogen-activated protein kinase cascade to treat cancer","volume":"4","author":"Sebolt-Leopold","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.intimp.2025.116037_bb0205","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","article-title":"Epithelial-mesenchymal transitions in development and disease","volume":"139","author":"Thiery","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2025.116037_bb0210","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.3389\/fimmu.2020.01280","article-title":"Cancer stem cells-origins and biomarkers: perspectives for targeted personalized therapies","volume":"11","author":"Walcher","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.116037_bb0215","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJMoa060570","article-title":"DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy","volume":"355","author":"Olaussen","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2025.116037_bb0220","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrc3181","article-title":"BRCA1 and BRCA2: different roles in a common pathway of genome protection","volume":"12","author":"Roy","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.intimp.2025.116037_bb0225","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s11094-023-02790-8","article-title":"Pharmacological strategies for overcoming multidrug resistance to chemotherapy","volume":"56","author":"Fedotcheva","year":"2023","journal-title":"Pharm. Chem. J."},{"key":"10.1016\/j.intimp.2025.116037_bb0230","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1146\/annurev-med-050913-022545","article-title":"Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors","volume":"66","author":"Lord","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.intimp.2025.116037_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2021.05.012","article-title":"The reversal of chemotherapy-induced multidrug resistance by nanomedicine for cancer therapy","volume":"335","author":"Liu","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.intimp.2025.116037_bb0240","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40164-021-00206-5","article-title":"MiRNA-mediated EMT and CSCs in cancer chemoresistance","volume":"10","author":"Dong","year":"2021","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2025.116037_bb0245","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nnano.2007.387","article-title":"Nanocarriers as an emerging platform for cancer therapy","volume":"2","author":"Peer","year":"2007","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.intimp.2025.116037_bb0250","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJMoa060570","article-title":"DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy","volume":"355","author":"Olaussen","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2025.116037_bb0255","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/sj.bjc.6600859","article-title":"BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells","volume":"88","author":"Tassone","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.intimp.2025.116037_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2020.101417","article-title":"Fibroblast heterogeneity in tumor micro-environment: role in immunosuppression and new therapies","volume":"48","author":"Mhaidly","year":"2020","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.intimp.2025.116037_bb0265","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20112767","article-title":"TGF-beta-mediated epithelial-mesenchymal transition and Cancer metastasis","volume":"20","author":"Hao","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.116037_bb0270","doi-asserted-by":"crossref","first-page":"12425","DOI":"10.1073\/pnas.1106645108","article-title":"Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem\/initiating cells","volume":"108","author":"Jinushi","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.intimp.2025.116037_bb0275","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2025.116037_bb0280","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The nature of myeloid-derived suppressor cells in the tumor microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol."},{"key":"10.1016\/j.intimp.2025.116037_bb0285","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/jnci\/djm135","article-title":"Drug resistance and the solid tumor microenvironment","volume":"99","author":"Tredan","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.intimp.2025.116037_bb0290","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13046-019-1161-8","article-title":"Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK\/STAT3\/PD-L1 pathway","volume":"38","author":"Shen","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2025.116037_bb0295","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","article-title":"Toxicities of immunotherapy for the practitioner","volume":"33","author":"Weber","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.116037_bb0300","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3389\/fonc.2018.00152","article-title":"Therapeutic antibodies for myeloid neoplasms-current developments and future directions","volume":"8","author":"Sch\u00fcrch","year":"2018","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2025.116037_bb0305","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3390\/cancers15020329","article-title":"A subset of PD-1-expressing CD56bright NK cells identifies patients with good response to immune checkpoint inhibitors in lung Cancer","volume":"15","author":"Gasc\u00f3n-Ruiz","year":"2023","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.intimp.2025.116037_bb0310","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1111\/cas.13072","article-title":"Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy","volume":"107","author":"Zhang","year":"2016","journal-title":"Cancer Sci."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925020260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925020260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T19:44:36Z","timestamp":1768938276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925020260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":60,"alternative-id":["S1567576925020260"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.116037","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Study on the mechanism of PSENEN in modulating cisplatin resistance in NSCLC through stromal cell interactions","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.116037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"116037"}}